Risk adjusted net present value: What is the current valuation of Atai Life Sciences’s RL-007?
RL-007 is a small molecule commercialized by Atai Life Sciences, with a leading Phase II program in Diabetic Neuropathic Pain.
RL-007 is a small molecule commercialized by Atai Life Sciences, with a leading Phase II program in Diabetic Neuropathic Pain.
What's Your Reaction?
